|
US4418068A
(en)
|
1981-04-03 |
1983-11-29 |
Eli Lilly And Company |
Antiestrogenic and antiandrugenic benzothiophenes
|
|
GB8327256D0
(en)
|
1983-10-12 |
1983-11-16 |
Ici Plc |
Steroid derivatives
|
|
TW366342B
(en)
|
1992-07-28 |
1999-08-11 |
Lilly Co Eli |
The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
|
|
US5478847A
(en)
|
1994-03-02 |
1995-12-26 |
Eli Lilly And Company |
Methods of use for inhibiting bone loss and lowering serum cholesterol
|
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
|
ES2204932T3
(es)
|
1994-09-12 |
2004-05-01 |
Eli Lilly And Company Limited |
Moduladores serotonergicos.
|
|
US5880137A
(en)
|
1996-04-19 |
1999-03-09 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
|
US5780497A
(en)
|
1996-04-19 |
1998-07-14 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
|
TW397821B
(en)
|
1996-04-19 |
2000-07-11 |
American Home Produits Corp |
3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
|
|
US5998402A
(en)
|
1996-04-19 |
1999-12-07 |
American Home Products Corporation |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
|
|
US6005102A
(en)
|
1997-10-15 |
1999-12-21 |
American Home Products Corporation |
Aryloxy-alkyl-dialkylamines
|
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
|
UA68365C2
(en)
|
1997-11-06 |
2004-08-16 |
Wyeth Corp |
Peroral contraception by combination of anti-estrogen and progestin
|
|
US6583170B1
(en)
|
1998-05-15 |
2003-06-24 |
Wyeth |
2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
|
|
US6479535B1
(en)
|
1998-05-15 |
2002-11-12 |
Wyeth |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
WO2002003988A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating neuropeptide y-related conditions
|
|
WO2002003989A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating sphincter incontinence
|
|
JP2004502729A
(ja)
|
2000-07-06 |
2004-01-29 |
ワイス |
Ssriおよびエストロゲン剤の組み合わせ
|
|
AU2001273125A1
(en)
|
2000-07-06 |
2002-01-21 |
American Home Products Corporation |
Combinations of bisphosphonates, estrogenic agents and optionally estrogens
|
|
EP1359940A2
(en)
|
2000-07-06 |
2003-11-12 |
Wyeth |
Combinations of statins, estrogenic agents and optionally estrogens
|
|
AU2001271706A1
(en)
|
2000-07-06 |
2002-01-21 |
American Home Products Corporation |
Use of substituted indole compounds for treating breast disorders
|
|
AU2001271784A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Therapy for prosthesis-related bone degeneration
|
|
US6509332B2
(en)
|
2000-07-06 |
2003-01-21 |
Wyeth |
Methods of treating excessive intraocular pressure
|
|
EP1296674A2
(en)
|
2000-07-06 |
2003-04-02 |
Wyeth |
Use of substituted indole compounds for increasing nitric oxide synthase activity
|
|
AR030064A1
(es)
|
2000-07-06 |
2003-08-13 |
Wyeth Corp |
Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
|
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
|
ATE278421T1
(de)
|
2000-08-11 |
2004-10-15 |
Wyeth Corp |
Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
|
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
EP1417169A2
(en)
|
2001-08-11 |
2004-05-12 |
Bristol-Myers Squibb Pharma Company |
Selective estrogen receptor modulators
|
|
NZ534069A
(en)
|
2002-01-22 |
2007-03-30 |
Warner Lambert Co |
2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
|
|
US8076352B2
(en)
|
2004-03-15 |
2011-12-13 |
Ptc Therapeutics, Inc. |
Administration of carboline derivatives useful in the treatment of cancer and other diseases
|
|
US7767689B2
(en)
|
2004-03-15 |
2010-08-03 |
Ptc Therapeutics, Inc. |
Carboline derivatives useful in the treatment of cancer
|
|
US7601840B2
(en)
|
2004-03-15 |
2009-10-13 |
Ptc Therapeutics, Inc. |
Carboline derivatives useful in the inhibition of angiogenesis
|
|
US7745625B2
(en)
|
2004-03-15 |
2010-06-29 |
Bristol-Myers Squibb Company |
Prodrugs of piperazine and substituted piperidine antiviral agents
|
|
US7399767B2
(en)
|
2005-01-21 |
2008-07-15 |
Ortho-Mcneil Pharmaceutical, Inc. |
Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
|
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
|
WO2010138659A1
(en)
|
2009-05-27 |
2010-12-02 |
Ptc Therapeutics, Inc. |
Methods for treating brain tumors
|
|
HUE052510T2
(hu)
|
2009-05-27 |
2021-05-28 |
Ptc Therapeutics Inc |
Módszerek a rák és a nem daganatos állapotok kezelésére
|
|
WO2010138695A1
(en)
|
2009-05-27 |
2010-12-02 |
Ptc Therapeutics, Inc. |
Methods for treating neurofibromatosis
|
|
WO2010138706A1
(en)
|
2009-05-27 |
2010-12-02 |
Ptc Therapeutics, Inc. |
Methods for treating breast cancer
|
|
EP3205648A1
(en)
|
2010-06-10 |
2017-08-16 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
CA2819299A1
(en)
|
2010-12-24 |
2012-06-28 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
|
EP2791132A4
(en)
|
2011-12-14 |
2015-08-05 |
Seragon Pharmaceuticals Inc |
ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
|
BR112014014767A2
(pt)
|
2011-12-16 |
2017-06-13 |
Olema Pharmaceuticals Inc |
novos compostos de benzopirano, composições e usos dos mesmos
|
|
AP2015008858A0
(en)
|
2013-05-28 |
2015-11-30 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
BR112015030595A2
(pt)
|
2013-06-19 |
2017-07-25 |
Seragon Pharmaceuticals Inc |
moduladores de receptor de estrogênio de azetidina e usos dos mesmos
|
|
EA031077B1
(ru)
|
2013-06-19 |
2018-11-30 |
Серагон Фармасьютикалз, Инк. |
Модулятор рецептора эстрогена и его применения
|
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
|
SG11201607334YA
(en)
*
|
2014-03-13 |
2016-10-28 |
Hoffmann La Roche |
Therapeutic combinations with estrogen receptor modulators
|
|
ES2939940T3
(es)
|
2014-03-28 |
2023-04-28 |
Univ Duke |
Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
|
|
TWI784255B
(zh)
|
2014-12-18 |
2022-11-21 |
瑞士商赫孚孟拉羅股份公司 |
四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
|
|
MX384605B
(es)
|
2015-04-29 |
2025-03-14 |
Radius Pharmaceuticals Inc |
Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
|
|
WO2017059139A1
(en)
*
|
2015-10-01 |
2017-04-06 |
Olema Pharmaceuticals, Inc. |
TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
|
|
CN109843882A
(zh)
|
2016-06-16 |
2019-06-04 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
|
US20180002344A1
(en)
|
2016-06-16 |
2018-01-04 |
Genentech, Inc. |
Heteroaryl estrogen receptor modulators and uses thereof
|
|
AU2017336564A1
(en)
*
|
2016-09-27 |
2019-03-14 |
Radius Pharmaceuticals, Inc. |
Methods for treating ovarian cancer
|
|
UA125824C2
(uk)
|
2016-10-24 |
2022-06-15 |
Астразенека Аб |
6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
|
|
IL298518B2
(en)
*
|
2017-04-28 |
2025-05-01 |
Hoffmann La Roche |
Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation
|
|
LT3810283T
(lt)
|
2018-06-21 |
2023-08-25 |
F. Hoffmann-La Roche Ag |
3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
|
|
MD3820874T2
(ro)
|
2018-07-12 |
2023-05-31 |
Lilly Co Eli |
Degradanți selectivi ai receptorului estrogen
|
|
TWI702219B
(zh)
|
2018-07-12 |
2020-08-21 |
美商美國禮來大藥廠 |
選擇性雌激素受體降解劑
|
|
KR20210035211A
(ko)
|
2018-07-23 |
2021-03-31 |
에프. 호프만-라 로슈 아게 |
Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
|
|
AU2019321588C1
(en)
|
2018-08-17 |
2026-05-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for the treatment of breast cancer
|
|
CA3144791A1
(en)
|
2019-07-07 |
2021-01-14 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
|
MX2022010425A
(es)
|
2020-03-06 |
2022-09-07 |
Olema Pharmaceuticals Inc |
Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
|